Funding momentum ARPA-H backing and a recent 46M award signal strong validation and potential for expansion of sonodynamic therapy programs, indicating potential for collaboration, licensing, and grant-backed pilot studies.

Clinical partnerships Ongoing collaborations with Ivy Brain Tumor Center and Insightec Aligns with institutions skilled in MR-guided focused ultrasound, presenting openings for co-development, clinical trials, and joint commercialization opportunities.

Therapy expansion Portfolio focus on a first-in-class non-invasive SDT platform for glioblastoma and blood cancers suggests cross-application sales paths to research clinics and hospitals treating these indications.

Tech stack leverage Adoption of widely deployed cloud and collaboration tools indicates readiness for enterprise-grade deployment, partner integrations, and data-sharing capabilities to support multi-site trials and KOL networks.

Market positioning Clinical-stage company with a 10–25M revenue band and sizable funding positions it as a potential strategic partner for device-makers, contract research organizations, and specialty oncology distributors seeking innovative SDT solutions.